Should You Buy Pfizer Stock in Singapore in 2025?
Is it the right time to buy Pfizer?
ScorePfizer Inc. (PFE) continues to capture attention in Singapore's investor community as a global leader in pharmaceuticals, currently trading at approximately $25.38 USD with a recent average daily volume of 46.3 million shares. Recent quarters underscore the company's resilience: despite a slight dip in revenue versus Q1 2024, Pfizer handily surpassed earnings expectations, reflecting excellent cost management and improved profitability. The approval of new therapies and a robust late-stage pipeline, including progress in hemophilia treatment and next-generation mRNA programs, demonstrate Pfizer's ongoing commitment to innovation. Recent FDA approvals, coupled with plans to submit key regulatory filings in 2025, provide further potential catalysts for the stock. The healthcare sector remains defensive and well positioned for long-term demand, particularly as the global population ages. Market sentiment is moderately optimistic, supported by a 6.78% dividend yield and consensus guidance reaffirmed by management. Analyst consensus from more than 11 national and international banks places a target price at $33.00 USD, highlighting renewed confidence in Pfizer's capacity for sustainable growth and value creation. For Singapore investors seeking stable returns and exposure to healthcare innovation, Pfizer merits thoughtful consideration.
- ✅Attractive 6.78% dividend yield for steady income potential.
- ✅Robust late-stage pipeline with strong regulatory momentum.
- ✅Solid cost control; recent earnings beat expectations despite revenue dip.
- ✅Global sales footprint, well diversified by therapy and geography.
- ✅Resilient, defensive sector benefiting from ageing demographics.
- ❌Post-COVID revenue transition requires continued new product success.
- ❌Competition intensifying in key segments, notably biosimilars and oncology.
Score- ✅Attractive 6.78% dividend yield for steady income potential.
- ✅Robust late-stage pipeline with strong regulatory momentum.
- ✅Solid cost control; recent earnings beat expectations despite revenue dip.
- ✅Global sales footprint, well diversified by therapy and geography.
- ✅Resilient, defensive sector benefiting from ageing demographics.
Is it the right time to buy Pfizer?
- ✅Attractive 6.78% dividend yield for steady income potential.
- ✅Robust late-stage pipeline with strong regulatory momentum.
- ✅Solid cost control; recent earnings beat expectations despite revenue dip.
- ✅Global sales footprint, well diversified by therapy and geography.
- ✅Resilient, defensive sector benefiting from ageing demographics.
- ❌Post-COVID revenue transition requires continued new product success.
- ❌Competition intensifying in key segments, notably biosimilars and oncology.
Score- ✅Attractive 6.78% dividend yield for steady income potential.
- ✅Robust late-stage pipeline with strong regulatory momentum.
- ✅Solid cost control; recent earnings beat expectations despite revenue dip.
- ✅Global sales footprint, well diversified by therapy and geography.
- ✅Resilient, defensive sector benefiting from ageing demographics.
- What is Pfizer?
- How much is Pfizer stock?
- Our Full Analysis of Pfizer Stock
- How to buy Pfizer stock in Singapore
- Our 7 tips for buying Pfizer stock
- The latest news about Pfizer
- FAQ
- On the same topic
Why trust HelloSafe ?
At HelloSafe, our expert has been tracking the performance of Pfizer for over three years. Every month, hundreds of thousands of users in Singapore trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, paid by Pfizer.
What is Pfizer?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | U.S.-based global pharmaceutical leader with broad international exposure. |
| 💼 Market | NYSE | Listed on the New York Stock Exchange; highly liquid and accessible to SG investors. |
| 🏛️ ISIN code | US7170811035 | Internationally recognized security identification; ensures reliable cross-border trading. |
| 👤 CEO | Dr. Albert Bourla | Renowned for strategic pipeline management and cost control. |
| 🏢 Market cap | $144.29 billion USD | Among top world pharma companies, reflecting scale and investor confidence. |
| 📈 Revenue | $13.72 billion USD (Q1 2025) | Revenue remains robust, despite a year-on-year decline after COVID-19 tailwinds. |
| 💹 EBITDA | $4.45 billion USD (Q1 2025)* | Solid cash generation supports ongoing R&D and dividend payments (*estimated for 2025). |
| 📊 P/E Ratio (Price/Earnings) | 18.39 | Attractive relative to sector; indicates balanced growth expectations and fair value. |
How much is Pfizer stock?
The price of Pfizer stock is rising this week. As of now, Pfizer trades at USD 25.38, showing a 24-hour increase of USD 0.06 and a robust 4.70% weekly gain. The company’s market capitalisation is USD 144.29 billion, with a 3-month average daily volume of 46.3 million shares. Pfizer’s current Price/Earnings (P/E) ratio is 18.39, supported by a strong annual dividend yield of 6.78% and a low beta of 0.49. The stock’s combination of steady performance and low volatility makes it appealing for Singapore investors seeking balance and resilient returns.
Our Full Analysis of Pfizer Stock
We have carefully reviewed Pfizer's latest financial results, assessed its stock’s remarkable performance over the past three years, and synthesised insights from financial indicators, technical signals, peer comparisons, and our proprietary market algorithms. This multifaceted approach aims to provide retail and institutional investors with a holistic, data-driven perspective. So, why might Pfizer stock once again become a strategic entry point into the global healthcare sector in 2025?
Recent performance and market context
Pfizer’s share price currently stands at USD 25.38, with a weekly gain of 4.70% and an intraday rise of USD 0.06. This strong rebound is set against a backdrop of renewed market confidence in large-cap healthcare stocks and robust institutional flows into the sector. The company’s market capitalisation holds steady at USD 144.29 billion, and its low beta of 0.49 suggests resilience in turbulent equity markets, a valuable attribute for Singapore-based investors seeking stability amid volatility.
On the events front, Pfizer continues to stand out with strategic wins: securing seven new FDA approvals in 2023, outpacing all competitors, and strengthening its global brand recognition. The past quarter saw the company significantly beat consensus earnings per share by 39%, thanks to disciplined cost control and operational efficiency, even as top-line revenue missed slightly due to sector-wide post-COVID adjustments. Collectively, these positives position Pfizer as a refuge for those seeking solid, yield-backed opportunities within a diversifying global portfolio.
Macroeconomically, Singapore’s continued focus on healthcare innovation, the city’s status as a regional biotech hub, and demographic trends play directly into Pfizer’s business model. Pfizer’s expansive global reach—around 40% of revenues sourced internationally and robust emerging market momentum—aligns well with the vibrancy and growth orientation of the SG market.
Technical analysis
Technical indicators further bolster the bullish case for Pfizer. The Relative Strength Index (RSI) stands at 66.69, signalling near-term momentum while still providing room before entering overbought territory. The MACD at +0.23 and a Williams %R of –26.83 both corroborate the ongoing buy signal, all the more convincing as they align with rising price trends.
What’s particularly compelling is Pfizer’s price trading above all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day measures. This bullish structure, backed by a robust 50-day average of USD 24.63, provides technical traders confidence in the uptrend’s sustainability. The crucial support zone at USD 25.20, close to the influential 200-day average, offers a defined risk level, while initial resistance has been identified at USD 26.89—a confirmation of breakout potential. The technical consensus remains a “Strong Buy,” reflecting broad market endorsement.
Fundamental analysis
From a fundamental perspective, Pfizer’s value proposition is built on strong profitability, consistent dividend delivery, and sector leadership. Despite a momentary year-on-year dip in first-quarter 2025 revenues to USD 13.72 billion (reflecting normalisation from pandemic peaks), adjusted earnings per share came in at USD 0.92—an impressive 39% above consensus. The company maintains a net margin of 22%, one of the most robust in global pharma, underlining efficient capital allocation and operational execution.
Pfizer’s valuation remains compelling with a price-to-earnings (P/E) ratio of 18.39 and a forward P/E of just 8.69, significantly below healthcare sector averages for a firm of this scale and diversification. With an annual dividend yield of 6.78%—one of the highest among blue-chip S&P 500 stocks—investors are paid to wait for the next upcycle. The stability of this payout, supported by recurring global product sales and prudent financial management, reflects a resilient model designed to withstand market and sector cycles.
- A pipeline covering oncology, vaccines, and specialty medicine, with blockbuster franchises like Eliquis, Prevnar, and Ibrance.
- Decades of blue-chip branding and R&D strength, reaffirmed by a 2025 guidance for international sales growth.
- A well-capitalised balance sheet, providing ample room for innovation and bolt-on acquisitions.
Volume and liquidity
Pfizer’s trading volume is both consistent and substantial, with a 3-month average of 46.3 million shares daily. This level of liquidity assures both retail and institutional investors in Singapore of tight bid-ask spreads and the ability to efficiently scale positions without affecting market dynamics. The company’s generous free float—5.67 billion shares—ensures the valuation remains dynamic and absorbs shocks, providing greater security on entry and exit for those managing larger allocations or seeking trading flexibility.
A healthy balance between institutional and retail holdings further supports sustained demand, resulting in orderly price discovery and smoothing out the impact of short-term market turbulence.
Catalysts and positive outlook
Pfizer is poised for growth on multiple fronts. The company’s rich pipeline is a major catalyst, with regulatory submissions for vepdegestrant expected in 2025, promising new oncology data in 2026, and expansion into cutting-edge mRNA vaccines for flu and shingles. These innovations are likely to fuel the next cycle of revenue acceleration and headline-grabbing partnerships.
M&A remains a recurring theme, as management signals willingness and financial capability to capitalise on emerging biotech opportunities. On the ESG front, Pfizer’s sustainability initiatives and global access programmes further bolster its long-term relevance and appeal, especially as institutional capital increasingly rewards responsible, impact-oriented companies.
Sector-wise, global demographic tailwinds, rising healthcare spending in ASEAN, and Singapore’s high per-capita medical expenditure amplify the relevance of allocating to global leaders such as Pfizer. Regulatory landscapes remain constructive, with expedited drug approvals and broadening payer coverage worldwide. All these drivers crystallise into an environment rich with potential upward re-ratings.
Investment strategies
- Short term: Recent trading above key technical supports and resilience in turbulent sessions suggest a favourable moment for tactical entries. The upcoming ex-dividend date on 25 July 2025 offers a near-term catalyst for yield-focused investors.
- Medium term: Expected positive developments in the pipeline, including pivotal Phase 3 trial results and regulatory updates, provide strong reasons to anticipate appreciation over the next 6–12 months. With strong technical and fundamental underpinnings, Pfizer’s consensus price target of USD 28.00 remains in view, and the +30% calculated potential (USD 33.00) underpins upside potential.
- Long term: For those seeking to capture the benefits of product innovation, defensive earnings, and global healthcare expansion, Pfizer’s diversified portfolio and disciplined capital deployment argue for a core position in any forward-looking portfolio. The sustained high dividend helps offset volatility, while long-term prospects look bright as the business advances towards the next phase of growth.
Investors might consider scaling in at technically significant levels or ahead of pipeline updates, balancing their allocation by risk tolerance and the desire for yield versus capital growth.
Is it the right time to buy Pfizer?
Pfizer’s current market position—underscored by liquidity, profitability, and innovation—seems to represent an excellent opportunity for new and existing investors. With a bullish technical structure, attractive valuation multiples, hefty dividend payout, and a robust, event-rich pipeline, the stock stands out for both tactical traders and patient, income-oriented buyers. Its global reach and alignment with dynamic healthcare trends in Singapore and the broader Asian region further amplify its strategic appeal.
While modest risks remain, notably the post-pandemic revenue recalibration and competitive pressure in biosimilars, these are counterbalanced by market-leading R&D commitment and operational consistency. The coming quarters are likely to shine a light on new, high-value product launches and margin expansion, paving the way for a new bullish phase in Pfizer.
In summary, all signals—technical, fundamental, sectoral, and statistical—justify renewed interest in Pfizer. For Singapore investors seeking a rare blend of reliability, yield, and innovation, Pfizer appears well positioned to deliver strong returns and reinforce its leadership in global healthcare as 2025 unfolds. Now is a compelling time to consider this stock as a core holding for the next investment cycle.
How to buy Pfizer stock in Singapore
Buying Pfizer stock online in Singapore is both simple and secure when using a reputable, MAS-regulated broker. Investors can choose between two main methods: buying Pfizer shares directly (spot/cash purchase), which makes you a shareholder, or trading Contracts for Difference (CFDs), which allows you to speculate on price movements with leverage. Each method has different risks and fee structures. To help you select the provider best suited to your needs, you’ll find a broker comparison further down this page.
Spot buying
Cash purchase of Pfizer stock means you buy and own the actual shares, benefiting from any dividends and capital gains. Typically, Singapore brokers charge a fixed commission per trade, often around SGD 5 to 10, plus possible exchange fees. This is the most straightforward approach for long-term investors.
Gain scenario
If the Pfizer share price is $25.38 USD, you can buy around 39 shares with a $1,000 stake, including a brokerage fee of around $5.
If the share price rises by 10%, your shares are now worth $1,100.
Result: +$100 gross gain, i.e. +10% on your investment.
Trading via CFD
CFD trading on Pfizer allows you to profit from price up or down without owning the shares. With CFDs, you pay a spread (the difference between buy/sell prices) and may incur overnight financing charges if you keep positions open for more than a day. CFDs permit the use of leverage, amplifying both gains and losses, making them suitable for short-term and active trading strategies.
CFD Position with Leverage: Gain Scenario
You open a CFD position on Pfizer shares, with 5x leverage. This gives you a market exposure of $5,000.
✔️ Gain scenario:
If the stock rises by 8%, your position gains 8% × 5 = 40%.
Result: +$400 gain, on a bet of $1,000 (excluding fees).
Final advice
Before investing, always compare brokers' commissions, spreads, and trading conditions to find the option best suited to your goals. Whether you choose to own Pfizer shares directly or prefer the flexibility of CFDs, the ideal method depends on your investment horizon, risk appetite, and strategy. For more guidance, refer to the broker comparison featured below.
Check out the best brokers in Singapore!Compare brokersOur 7 tips for buying Pfizer stock
| 📊 Step | 📝 Specific tip for Pfizer |
|---|---|
| Analyze the market | Assess global healthcare trends and Singapore’s high medical spending, both boosting demand for Pfizer and supporting its growth. |
| Choose the right trading platform | Select a MAS-regulated broker that offers access to NYSE with reasonable commissions for safer and cost-effective Pfizer investments. |
| Define your investment budget | Decide your allocation for Pfizer, balancing its attractive dividend with diversification in your broader portfolio. |
| Choose a strategy (short or long term) | For stable dividend income, consider a long-term position in Pfizer, given its resilient track record and pipeline. |
| Monitor news and financial results | Follow quarterly earnings, new product approvals, and updates from Pfizer that can influence stock price direction. |
| Use risk management tools | Make use of limit and stop-loss orders to safeguard your Pfizer investment against market swings. |
| Sell at the right time | Review your position after major company news or dividend dates, taking profits when the stock reaches technical resistance. |
The latest news about Pfizer
Pfizer stock has gained 4.7% over the past week, benefiting from technical “strong buy” signals. The upward movement is supported by bullish trends in major technical indicators, including the RSI, MACD, and key moving averages. This sustained momentum points to renewed investor confidence, with Pfizer now trading well above support and moving closer to identified resistance levels, a development closely followed by major brokers in Singapore.
Pfizer reaffirms its leadership in the region through robust product distribution and new vaccine launches in SG. In Singapore, Pfizer continues to expand access to its cardiovascular and vaccine portfolio—Eliquis, Prevnar, and pneumococcal vaccines feature in local public and private healthcare settings. This broadening distribution network supports revenue stability and enhances Pfizer’s profile as a key healthcare innovator within Singapore’s high-standard regulatory environment.
The company’s recent dividend announcement secures a yield of 6.78%, appealing to SG income-focused investors. Pfizer’s upcoming ex-dividend date is 25 July 2025, underscoring its commitment to stable and growing shareholder returns. With annual dividends at $1.72 per share, this payout is particularly attractive to Singapore investors looking for defensive, income-oriented positions in global healthcare leaders.
Pfizer’s ongoing clinical development is driving optimism, with pipeline catalysts expected in oncology and mRNA. Investors are anticipating major regulatory filings and trial results, including next-generation cancer therapies and mRNA vaccines for seasonal flu and shingles. These innovations not only underpin Pfizer’s growth outlook, but also fit the strategic interests of Singapore’s government in boosting advanced biotech capabilities.
Steady net profit margins and cost discipline reinforce Pfizer’s capacity for long-term value creation. The latest quarterly update highlights a stable 22% net margin and earnings surpassing consensus forecasts, achieved via effective cost management. This combination of profitability and innovation assures Singaporean investors of Pfizer’s resilience and flexibility in adapting to shifting global pharmaceuticals demand.
FAQ
What is the latest dividend for Pfizer stock?
Pfizer currently pays a regular dividend. The latest annual dividend stands at $1.72 per share, paid quarterly at $0.43 each. The next ex-dividend date is 25 July 2025, with payment slated for 2 September 2025. The current yield is among the highest in the sector, and the group is known for consistently increasing dividends over time.
What is the forecast for Pfizer stock in 2025, 2026, and 2027?
Based on the current price of $25.38, the projection for end-2025 is $33.00, for end-2026 is $38.10, and for end-2027 is $50.76. Pfizer’s strong pipeline, solid financials, and positive technical signals support a constructive multi-year outlook.
Should I sell my Pfizer shares?
Holding Pfizer shares may make sense given its attractive dividend, solid balance sheet, and leadership in innovation. The current valuation remains reasonable, and the company's global reach adds resilience. With a robust R&D program and long-term growth plans, Pfizer stands out as a defensive and growth-oriented option in the healthcare sector.
How are dividends and capital gains from Pfizer shares taxed for Singapore investors?
Dividends from Pfizer are subject to a 30% US withholding tax, but there is no Singapore tax on foreign dividends for individuals. Capital gains on Pfizer shares are tax-free in Singapore. Investors should note that US regulations can affect heirs or estate transfers.
What is the latest dividend for Pfizer stock?
Pfizer currently pays a regular dividend. The latest annual dividend stands at $1.72 per share, paid quarterly at $0.43 each. The next ex-dividend date is 25 July 2025, with payment slated for 2 September 2025. The current yield is among the highest in the sector, and the group is known for consistently increasing dividends over time.
What is the forecast for Pfizer stock in 2025, 2026, and 2027?
Based on the current price of $25.38, the projection for end-2025 is $33.00, for end-2026 is $38.10, and for end-2027 is $50.76. Pfizer’s strong pipeline, solid financials, and positive technical signals support a constructive multi-year outlook.
Should I sell my Pfizer shares?
Holding Pfizer shares may make sense given its attractive dividend, solid balance sheet, and leadership in innovation. The current valuation remains reasonable, and the company's global reach adds resilience. With a robust R&D program and long-term growth plans, Pfizer stands out as a defensive and growth-oriented option in the healthcare sector.
How are dividends and capital gains from Pfizer shares taxed for Singapore investors?
Dividends from Pfizer are subject to a 30% US withholding tax, but there is no Singapore tax on foreign dividends for individuals. Capital gains on Pfizer shares are tax-free in Singapore. Investors should note that US regulations can affect heirs or estate transfers.
On the same topic
